Loading…
← CockpitCompetitor Analysis › 002099.SZ Zhejiang Hisoar Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Zhejiang Hisoar Pharmaceutical Co., Ltd. Class A002099.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Zhejiang maker of pharmaceutical intermediates and APIs, including anesthetic and other fine-chemical active ingredients.

≈ A small Chinese API/CDMO supplierMomentum leader 88
Mkt cap
$1.33B
US dollars, full cap
Free float
52%
of shares outstanding
$/day
$14.3M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-5.9 pp
WACC 5.8%
Hurdle
n/a
no reverse DCF
Next earnings
162 days
29 Apr 2027
Close · CNYCN¥5.55
1D-1.4%
1W-5.5%
1M-4.3%
3M+0.7%
6M-2.1%
YTD-11.1%
1Y-11.1%
ATR %4.5%
52w lowhigh38.9% off high

What Zhejiang Hisoar Pharmaceutical does

Zhejiang maker of pharmaceutical intermediates and APIs, including anesthetic and other fine-chemical active ingredients.

In one line: A small Chinese API/CDMO supplier.

Products and services

  • Anesthetic APIs
  • Other pharmaceutical intermediates
  • CDMO custom synthesis

Customers

  • Generic-drug formulators
  • Pharma companies

Where it sits in the supply chain

  • Pharmaceuticals
  • Active ingredients
  • Fine chemicals and APIs

What could go right

  • Global generic-drug demand for APIs

What could go wrong

  • API price competition
  • Environmental compliance costs

Moat: none (scale). Commodity API producer competing mainly on cost and regulatory filings.

Headquarters: Taizhou, Zhejiang, China · Employees: 2,736

Named competitors

Zhejiang Hisoar Pharmaceutical at a glance

Size Zhejiang Hisoar Pharmaceutical (002099.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.33B, the 1700th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥5.55 on 18 Nov 2026.

Performance Over six months the shares fell 2.1%, against -19.0% for the median peer and -20.0% for the China market (cap-weighted) — 6th highest of 20 in its peer set.

Growth Revenue grew 9.2% over the last twelve months (peer median +10.0%); the operating margin is -12.7% (peer median 11.1%).

Valuation It trades at 4.7× enterprise value to sales against a peer median of 3.5× (8th most expensive of 17).

Capital Return on invested capital runs 5.9 points below its cost of capital (5.8% WACC).

Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).

Relative performance

9010021 May 202621 Aug 202618 Nov 2026002099.SZ 94Peer median 83
Six months, rebased to 100: Zhejiang Hisoar Pharmaceutical against the median of its 20 peers (local-currency closes).

Zhejiang Hisoar Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥2.03BCN¥1.85BCN¥1.93BCN¥2.14BCN¥2.70B
Revenue growth—-4%-10%-21%—
Gross profitCN¥656MCN¥378MCN¥445MCN¥192MCN¥633M
EBITDAn/aCN¥228MCN¥202MCN¥88.9MCN¥425M
Net income-CN¥234M-CN¥91.1M-CN¥330M-CN¥420MCN¥88.0M
Free cash flow-CN¥154M-CN¥88.8MCN¥53.2MCN¥87.5M-CN¥63.2M
Capital expenditureCN¥90.2MCN¥74.5MCN¥122MCN¥153MCN¥179M
Total debtCN¥1.53BCN¥1.50BCN¥1.51BCN¥1.09BCN¥1.35B

Quarterly statements and history in the cockpit →

Zhejiang Hisoar Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%068760688293300181NANOMNKDINVAOCUL226950LBRX301263002332002020AMPH300204DMRA002099.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Zhejiang Hisoar Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%+100%0×50×100×150×068760688293300181NANOOCUL226950300204002099.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Zhejiang Hisoar Pharmaceutical is the large dot.

Zhejiang Hisoar Pharmaceutical competitors and peer comparison

Head to head with its named competitors (002099.SZ vs 603229.SS vs 600267.SS vs 600276.SS)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Zhejiang Hisoar Pharmaceutical 002099.SZ$1.33B-2%+9%-13%4.7×n/a
Zhejiang Ausun Pharmaceutical 603229.SS$824M-34%+1%0%6.5×n/a
Zhejiang Hisun Pharmaceutical 600267.SS$2.19B+14%-7%15%1.7×-9.7%
Jiangsu Hengrui Pharmaceuticals 600276.SS$45.7B-13%+6%27%8.0×13.4%

How Zhejiang Hisoar Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Zhejiang Hisoar Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure002099.SZPeer medianRank in peer set
1-month return-4.3%-2.3%9th lowest of 20
6-month return-2.1%-19.0%6th highest of 20
Distance from 52-week high-38.9%-40.0%10th highest of 20
Revenue growth (TTM)+9.2%+10.0%9th highest of 17
Operating margin-12.7%11.1%5th lowest of 17
EV / Sales4.7×3.5×8th most expensive of 17
ROIC minus cost of capital-5.9 pp-0.7 pp7th lowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Zhejiang Hisoar Pharmaceutical 002099.SZChina$1.33B-2%+9%-13%4.7×n/an/a
Celltrion Pharm 068760.KSSouth Korea$1.33B-23%+16%12%3.0×10.2%+18.1%
Shanghai OPM Biosciences 688293.SSChina$1.32B+36%+133%11%9.6×25.9%+23.1%
Zhejiang Jolly Pharmaceutical 300181.SZChina$1.34B-15%+17%20%3.0×3.9%+22.8%
Windward Bio WWBUnited States$1.31Bn/an/an/an/an/an/a
Nanobiotix NANO.PAFrance$1.35B-32%-77%-392%146.3×n/an/a
MannKind MNKDUnited States$1.31B+25%+32%-2%4.0×n/an/a
Innoviva INVAUnited States$1.31B-17%+12%38%2.2×-17.2%+3.9%
Ocular Therapeutix OCULUnited States$1.31B-26%-10%-681%17.0×n/an/a
OliX Pharmaceuticals 226950.KSSouth Korea$1.35B-51%+27%-384%125.0×n/an/a
LB Pharmaceuticals LBRXUnited States$1.30B+43%n/an/an/an/an/a
Guangdong Taienkang Pharmaceutical 301263.SZChina$1.30B-24%+2%-2%12.8×n/an/a
Zhejiang Xianju Pharmaceutical 002332.SZChina$1.28B-1%+8%11%2.0×-0.4%-1.3%
Zhejiang Jingxin Pharmaceutical 002020.SZChina$1.39B-19%+1%19%2.1×-9.6%+4.6%
Amphastar Pharmaceuticals AMPHUnited States$1.27B+64%+3%19%2.3×2.5%+15.5%
Staidson (Beijing) Biopharmaceuticals 300204.SZChina$1.26B-41%-24%-51%39.1×n/an/a
GH Research GHRSUnited States$1.25B-19%n/an/an/an/an/a
Sinopep-Allsino Bio Pharmaceutical 688076.SSChina$1.25B-16%+14%19%4.8×3.4%+27.9%
C.Q. Pharmaceutical 000950.SZChina$1.24B-27%-3%1%0.5×n/an/a
Damora Therapeutics DMRAUnited States$1.42B-5%n/an/an/an/an/a
Nippon Shinyaku 4516.TJapan$1.42B-20%+18%18%0.8×-18.1%+7.0%

Questions

Who are Zhejiang Hisoar Pharmaceutical's main competitors?
Named competitors: Zhejiang Ausun Pharmaceutical (603229.SS), Hisun Pharmaceutical (600267.SS), Jiangsu Hengrui (600276.SS). The cockpit's measured peer set (industry) also includes Celltrion Pharm (068760.KS), Shanghai OPM Biosciences (688293.SS), Zhejiang Jolly Pharmaceutical (300181.SZ), Windward Bio (WWB), Nanobiotix (NANO.PA), MannKind (MNKD).
Is Zhejiang Hisoar Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 4.7× against a peer median of 3.5×, 8th most expensive of 17 in its peer set.
How has Zhejiang Hisoar Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -2.1% against -19.0% for the median peer; over one year -11.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.